Grigore T. Popa University of Medicine and Pharmacy
Iasi, Romania

Grigore T. Popa University of Medicine and Pharmacy is a public university-level medical school located in Iași, Romania. It was named in honor of the scientist Grigore T. Popa. Wikipedia.

Time filter
Source Type

Radu C.-D.,Technical University Gheorghe Asachi | Parteni O.,Technical University Gheorghe Asachi | Ochiuz L.,Grigore T. Popa University of Medicine and Pharmacy
Journal of Controlled Release | Year: 2016

This paper presents data on the general properties and complexing ability of cyclodextrins and assessment methods (phase solubility, DSC tests and X-ray diffraction, FTIR spectra, analytical method). It focuses on the formation of drug deposits on the surface of a textile underlayer, using a cyclodextrin compound favoring the inclusion of a drug/active principle and its release onto the dermis of patients suffering from skin disorders, or for protection against insects. Moreover, it presents the kinetics, duration, diffusion flow and release media of the cyclodextrin drug for in vitro studies, as well as the release modeling of the active principle. The information focuses on therapies: antibacterial, anti-allergic, antifungal, chronic venous insufficiency, psoriasis and protection against insects. The pharmacodynamic agents/active ingredients used on cotton, woolen and synthetic textile fabrics are presented. © 2016 Elsevier B.V.

Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: REGIONS | Award Amount: 2.96M | Year: 2010

Thanks to the developments in Medical Imaging Diagnosis is earlier than ever. Physicians have more information and insight. Care is less invasive and less painful for patients. Access to tests and treatments is easier as imaging procedures are available in convenient settings, such as independent imaging centers. In addition, patient outcomes from fewer complications to saved livesare dramatically improved. And we are not at the end of our journey, yet!. The Next Generation of Medical Imaging is just here out of the integration and cross-disciplinary use of NanoMedicine, Pharmacological breakthroughs, Biotechnologies for healthcare and ICT combined with standard Medical Imaging evolution. Unfortunately, the healthcare sector is quite diverse and collaboration has been difficult as a result, so the challenge is to build expertise in the development of integrated systems that address unmet clinical needs while providing a solid and consistent network of R&D \ Innovation groups. Co-ordination and integration of Research-Driven Clusters under the so called Triple Helix III approach is a must in order to achieve the growth and competitiveness opportunities that Advanced Medical Imaging brings to the European society. AMI-4EUROPE is to co-ordinate, integrate and set up a newly defined EU-based Value Chain on Advanced, Cross-disciplinary and Integrated Medical Imaging by taking full advantage of all strengths that European stakeholders have while targeting the market niches that are arising as the Next Generation Medical Imaging unfolds itself out of the convergence of Nanomedicine, Pharmaceutical and Biotechnologies for healthcare and taking advantage of the ICT developments. Socio-economic impact at European level will be significant. Sustainability and synergy-searching are assured: Many regional governments are backing up AMI-4EUROPE.

Agency: European Commission | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2013-IAPP | Award Amount: 3.02M | Year: 2013

Advances in digital pathology are generating huge volumes of whole slide and tissue microarray images which are providing new insights into the causes of some of todays most devastating diseases. They also present tremendous opportunities for developing and evaluating new and more effective treatments that may revolutionize the care of patients with cancers and other diseases. The challenge is to exploit the new and emerging digital pathology technologies effectively in order to process and model all the heterogeneous tissue-derived data. This requires joint research projects and collaborative programmes between academia and industry. Thus, biomedical scientists will be equipped with broad knowledge and tools of modern imaging and data processing as well as analysis technologies, whereas engineers with have an understanding of the complex disease processes and the clinical needs. This will help developing efficient and innovative products to fulfil the needs of digital pathology. The AIDPATH project addresses this challenge through a focused research, including research training aiming to knowledge sharing and career development in this emerging multidisciplinary field. AIDPATH will research and develop: a) state of the art medical image display technology for digital pathology, b) novel image analysis solutions and knowledge discovery tools for future pathology diagnosis and research and c) state of the art solutions for biomarker evaluation and quantification. The first application will be breast cancer, though the applicability of the implemented methods and tools to other major diseases will be analysed.

Antoniu S.A.,Grigore T. Popa University of Medicine and Pharmacy
Multidisciplinary Respiratory Medicine | Year: 2012

Idiopathic pulmonary fibrosis is a rare, life threatening disease characterized by an anarchic fibrogenesis, limited survival and few therapeutic options. Its pathogenesis is complex and involves the interaction among various pathways driven by proinflammatory/profibrogenetic mediators such as platelet -derived growth factor, vascular endothelial growth factor or basic fibroblast growth factor. Given their prominent pathogenic roles in this disease such growth factor might be suitable therapeutic targets.In fact, the existing preclinical and clinical data demonstrated that their therapeutic inhibition results in a delayed progression of the pulmonary fibrosis and in the improvement of the disease outcome. BIBF 1120 is a potent triple blocker of the receptors of these growth factors which is currently evaluated as a potential therapy in the idiopathic pulmonary fibrosis. This review discusses the existing data supporting its potential use in this disease. © 2012 Antoniu; licensee BioMed Central Ltd.

Balan V.,Grigore T. Popa University of Medicine and Pharmacy | Verestiuc L.,Grigore T. Popa University of Medicine and Pharmacy
European Polymer Journal | Year: 2014

Due to its remarkable physicochemical and biological properties, chitosan is one of the most promising polymers for biomedical applications. The cationic nature of chitosan may induce thrombosis making it unsuitable as blood - contacting material. Nevertheless, in the last decade many researchers are attempting to modulate the biopolymer-blood interactions and to develop hemocompatible chitosan derivatives, which will broaden the biopolymer applications. This paper provides an overview of the strategies used to enhance chitosan hemocompatibility, focusing on two specific topics: (i) strategies based on chemical modifications of chitosan and (ii) strategies based on association of this biopolymer with compounds that exhibit complementary properties. It also highlights the current progress in the design of hemocompatible functionalized chitosan-based systems for biomedical applications such as: drug delivery, central nervous system disease treatment, theragnosis and cardiovascular applications. © 2014 Elsevier Ltd. All rights reserved.

Antoniu S.A.,Grigore T. Popa University of Medicine and Pharmacy
Expert Opinion on Therapeutic Targets | Year: 2014

Introduction: In asthma and chronic obstructive pulmonary disease (COPD), there is an unmet therapeutic need for the anti-inflammatory therapies, and the identification of therapeutic targets and potent corresponding therapies is necessary. Although inhaled corticosteroids and leukotriene modifiers are most effective in asthma they are still not always capable of appropriately controlling the disease. In COPD, the therapeutic gap is even larger because inhaled corticosteroids and other anti-inflammatory therapies are not beneficial in all disease subsets. Areas covered: The role of the 5-lipoxygenase-activating protein (FLAP) in generating proinflammatory molecules such as leukotrienes is discussed, highlighting, in particular, its potential as a therapeutic target in asthma and COPD. The preclinical data on FLAP inhibitors are discussed. The clinical data on the FLAP inhibitors investigated so far for these diseases are analyzed. Expert opinion: FLAP inhibitors have emerged during the past decade as a promising therapeutic class in asthma and COPD, but there exists only a limited amount of data supporting their efficacy in these diseases. This might be due to the fact that the development of some of the molecules discussed was abandoned. Such therapies might be of particular interest in COPD and in asthma-COPD overlap syndrome. © 2014 Informa UK, Ltd.

Antoniu S.,Grigore T. Popa University of Medicine and Pharmacy
Expert Opinion on Biological Therapy | Year: 2014

Introduction: Systemic lupus erythematosus is an autoimmune multiorgan disease in which the lack of an appropriate therapy can lead to rapid organ failure and death. Immunosuppressive therapies such as corticosteroids or cyclophosphamide can slow down the disease progression but sometimes other therapies are needed. Among such therapies, epratuzumab, an antiCD22 antibody, can be potentially efficacious in this disease. Areas covered: Discussion of the results from clinical studies evaluating the efficacy and safety of epratuzumab in patients with moderate or severe systemic lupus erythematosus. Expert opinion: The study demonstrates that epratuzumab can improve the quality of life and can reduce the disease activity burden, but the premature termination of the studies might have limited the generation of further efficacy data. © 2014 Informa UK, Ltd.

Stefanescu C.,Grigore T. Popa University of Medicine and Pharmacy | Ciobica A.,Al. I. Cuza University
Journal of Affective Disorders | Year: 2012

Oxidative and nitrosative stress (O&NS) could play an important role in the pathophysiology of major depression (MDD). The aim of the present work was to evaluate the specific activity of the main peripheral antioxidant defences (superoxide dismutase - SOD and glutathione peroxidase - GPX) and the level of malondialdehyde - MDA (a lipid peroxidation maker), in depressed patients, as compared to an age-matched control group. Also, we were interested to see if there are any differences between first episode vs. recurrent depression groups, in terms of oxidative stress markers. Additionally, we want it to investigate the effects of different antidepressant medication (mirtazapine, venlafaxine, tianeptine and escitalopram) on oxidative status of depressed patients. Our results showed an increased oxidative stress status in the serum of patients with MDD, expressed by a significant decrease of both SOD and GPX specific activities and a significant increase of the lipid peroxidation marker MDA, as compared to the control group. When we analyzed the oxidative stress status in depressed patients based on chronicity we observed significant decrease of SOD and GPX specific activities in recurrent depression group, as compared to the first episode group. Moreover, a very significant increase in MDA concentration was observed in recurrent depression patients, as compared to the first episode group. Our work provides additional evidences of increased oxidative stress in MDD, expressed by altered antioxidant enzyme activity and increased levels of lipid peroxidation. Also, it seems that sub-classifying depression into different subtypes, based on chronicity, can predict differences in the levels of some various oxidative stress markers. © 2012 Elsevier B.V.

Bild W.,Grigore T. Popa University of Medicine and Pharmacy | Ciobica A.,Al. I. Cuza University
Journal of Affective Disorders | Year: 2013

There is increasing evidence that besides the well-known angiotensin (Ang) II, other renin-angiotensin system (RAS) peptides, including Ang-(1-7), could have important effects at the central level. However, very few things are known about the central actions of Ang-(1-7), while the effects of its administration alone on anxiety have not been tested to date, to the best of our knowledge. In this way, we were interested in studying the effects of Ang-(1-7) intracerebroventricular administration on anxiety levels, as studied through some main behavioral parameters in the elevated plus maze, as well as the importance of Ang-(1-7) in the oxidative stress status from the amygdala, which is one of the key brain regions involved in mediating anxiety. We report here a possible anxiolytic-like effect of Ang-(1-7) administration, as demonstrated by the increased percentage of time spent and frequency of entries in the open arms of the elevated plus maze, as well as increased head-dipping behavior in the open arms and decreased stretching in closed arms. Also some antioxidant effects of Ang-(1-7) are suggested since a significant increase of GPX specific activity and a decrease of the main peroxidation marker MDA were observed in the amygdala. Moreover, we found a significant correlation between most of the behavioral parameters in the elevated plus maze and the levels of the oxidative stress markers. However, further studies are necessary in order to elucidate the effects of Ang-(1-7) administration on anxiety and oxidative stress status and also on the possible correlation that might exists between these aspects. © 2012 Elsevier B.V. All rights reserved.

Antoniu S.,Grigore T. Popa University of Medicine and Pharmacy
Expert Review of Anti-Infective Therapy | Year: 2015

In cystic fibrosis, chronic airways infection caused by Pseudomonas aeruginosa can be treated with inhaled antibiotics such as inhaled tobramycin, aztreonam or colistin. However, biofilm formation induced by this bacterium can reduce the effectiveness of such therapies and can contribute to antibiotic resistance. Inhaled antibiotic combination might represent an optimal antibiofilm strategy in this setting. This review discusses the rationale for combining the antibiotics as well as some emerging or existing combinations. Most of the combinations except for fosfomycin/tobramycin are at an early stage of development. The latter combination was found to be effective in Phase II clinical studies and is planned to be tested in Phase III trials. The clinical data on long-term efficacy are currently missing, but the existing evidence as well as the unmet therapeutic need can prompt the further evaluation of such compounds. © 2015 Informa UK, Ltd.

Loading Grigore T. Popa University of Medicine and Pharmacy collaborators
Loading Grigore T. Popa University of Medicine and Pharmacy collaborators